CIK 0000879169 · Large accelerated filer
INCYTE CORP
Sign in to watch- Ticker
- INCY
- Exchange
- Nasdaq
- Industry
- Services-Commercial Physical & Biological Research
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 943136539
- Phone
- 3024986700
- Business address
- 1801 AUGUSTINE CUT-OFF, WILMINGTON, DE, 19803
- Former names
- INCYTE INC, INCYTE GENOMICS INC, INCYTE PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $32,959,897
- in 5 filings, $33.0M under 10b5-1 plans
Net −$32,959,897. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-15 | CAGNONI PABLO J President, Global Head of R&D | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −4,551 | 4,551 | ||
| 2026-09-15 | CAGNONI PABLO J President, Global Head of R&D | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −6,477 | 20,356 | ||
| 2026-09-15 | CAGNONI PABLO J President, Global Head of R&D | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −9,233 | 18,466 | ||
| 2026-08-25 | Basi Ramitpal K EVP, Human Resources | Shares withheld for taxes | −504 | $129.72 | $65K | 10,993 |
| 2026-08-19 | CAGNONI PABLO J President, Global Head of R&D | Sale 10b5-1 | −10,801 | $125.56 | $1.4M | 183,200 |
| 2026-08-12 | CAGNONI PABLO J President, Global Head of R&D | Sale 10b5-1 | −10,803 | $120.04 | $1.3M | 194,001 |
| 2026-08-05 | Mayes Patrick A EVP & Chief Scientific Officer | Option exercise 10b5-1 | +2,207 | $106.47 | $235K | 63,648 |
| 2026-08-05 | Mayes Patrick A EVP & Chief Scientific Officer | Sale 10b5-1 | −2,207 | $123.99 | $274K | 61,441 |
| 2026-08-05 | Mayes Patrick A EVP & Chief Scientific Officer | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −2,207 | 0 | ||
| 2026-08-05 | CAGNONI PABLO J President, Global Head of R&D | Sale 10b5-1 | −10,640 | $122.69 | $1.3M | 204,804 |
| 2026-08-03 | Mayes Patrick A EVP & Chief Scientific Officer | Option exercise 10b5-1 | +6,055 | $105.43 | $638K | 67,496 |
| 2026-08-03 | Mayes Patrick A EVP & Chief Scientific Officer | Sale 10b5-1 | −6,055 | $120.43 | $729K | 61,441 |
| 2026-08-03 | Mayes Patrick A EVP & Chief Scientific Officer | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −6,055 | 0 | ||
| 2026-07-31 | Mayes Patrick A EVP & Chief Scientific Officer | Option exercise 10b5-1 | +2,918 | $61.18 | $179K | 66,546 |
| 2026-07-31 | Mayes Patrick A EVP & Chief Scientific Officer | Option exercise 10b5-1 | +2,284 | $64.25 | $147K | 68,830 |
| 2026-07-31 | Mayes Patrick A EVP & Chief Scientific Officer | Option exercise 10b5-1 | +2,709 | $61.76 | $167K | 71,539 |
| 2026-07-31 | Mayes Patrick A EVP & Chief Scientific Officer | Option exercise 10b5-1 | +3,148 | $68.62 | $216K | 74,687 |
| 2026-07-31 | Mayes Patrick A EVP & Chief Scientific Officer | Option exercise 10b5-1 | +2,072 | $71.93 | $149K | 76,759 |
| 2026-07-31 | Mayes Patrick A EVP & Chief Scientific Officer | Option exercise 10b5-1 | +9,459 | $72.27 | $684K | 86,218 |
| 2026-07-31 | Mayes Patrick A EVP & Chief Scientific Officer | Option exercise 10b5-1 | +2,623 | $74.78 | $196K | 88,841 |
Page 4 of 15 · 293 trades